BR112016026575A2 - Mirna Expression Signature in Thyroid Tumor Classification - Google Patents
Mirna Expression Signature in Thyroid Tumor ClassificationInfo
- Publication number
- BR112016026575A2 BR112016026575A2 BR112016026575A BR112016026575A BR112016026575A2 BR 112016026575 A2 BR112016026575 A2 BR 112016026575A2 BR 112016026575 A BR112016026575 A BR 112016026575A BR 112016026575 A BR112016026575 A BR 112016026575A BR 112016026575 A2 BR112016026575 A2 BR 112016026575A2
- Authority
- BR
- Brazil
- Prior art keywords
- tumor classification
- thyroid tumor
- expression signature
- mirna expression
- signature
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
a presente invenção fornece um método para classificação de tumores da tireoide através da análise dos padrões de expressão de micrornas específicos em amostras de aspiração com agulha fina. a classificação de tumor da tireoide de acordo com uma assinatura de expressão de microrna permite a otimização do diagnóstico e do tratamento, assim como a determinação de uma terapia específica para a assinatura.The present invention provides a method for classifying thyroid tumors by analyzing specific microorn expression patterns in fine needle aspiration samples. Thyroid tumor classification according to a microrna expression signature allows optimization of diagnosis and treatment, as well as the determination of a specific therapy for the signature.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461992531P | 2014-05-13 | 2014-05-13 | |
US201461992756P | 2014-05-13 | 2014-05-13 | |
US201462069353P | 2014-10-28 | 2014-10-28 | |
US201562139066P | 2015-03-27 | 2015-03-27 | |
PCT/US2015/030564 WO2015175660A1 (en) | 2014-05-13 | 2015-05-13 | Mirna expression signature in the classification of thyroid tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016026575A2 true BR112016026575A2 (en) | 2017-12-12 |
Family
ID=54480610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016026575A BR112016026575A2 (en) | 2014-05-13 | 2015-05-13 | Mirna Expression Signature in Thyroid Tumor Classification |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3143162A4 (en) |
JP (1) | JP6216470B2 (en) |
CN (1) | CN106460053A (en) |
BR (1) | BR112016026575A2 (en) |
CA (1) | CA2945531C (en) |
IL (1) | IL248639A0 (en) |
WO (1) | WO2015175660A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106434872A (en) * | 2016-08-11 | 2017-02-22 | 河南大学 | MiRNA molecule marker hsa-miR-152-3p for diagnosing type 2 diabetes, and application thereof |
CN107385093A (en) * | 2017-09-07 | 2017-11-24 | 青岛大学 | Primer composition and its application and application its product and product application method |
CN107723365B (en) * | 2017-09-11 | 2019-10-01 | 朱伟 | One kind blood plasma miRNA marker relevant to lung squamous cancer auxiliary diagnosis and its application |
CN108038352B (en) * | 2017-12-15 | 2021-09-14 | 西安电子科技大学 | Method for mining whole genome key genes by combining differential analysis and association rules |
CA3088939A1 (en) * | 2018-01-05 | 2019-07-11 | Visiongate, Inc. | Morphometric genotyping of cells using optical tomography for detecting tumor mutational burden |
BR102018003587A2 (en) * | 2018-02-23 | 2020-07-07 | Onkos Diagnósticos Moleculares Ltda Me | method and kit for detecting thyroid tumor type |
CN108721318B (en) * | 2018-05-16 | 2021-06-25 | 广东药科大学 | Application of miR-125b and chemotherapeutic agent in preparation of medicine for treating thyroid cancer |
JP7378739B2 (en) * | 2018-08-10 | 2023-11-14 | 東レ株式会社 | Kits, devices and methods for the detection of prostate cancer |
CN109700824A (en) * | 2019-01-08 | 2019-05-03 | 上海长海医院 | Application of the miR-31 and the like in the drug of preparation prevention or treatment blood vessel endothelium injury |
CN110499367B (en) * | 2019-08-09 | 2022-11-22 | 深圳市第二人民医院 | Biomarkers and uses thereof |
CN113025714B (en) * | 2021-03-23 | 2022-05-24 | 华中科技大学同济医学院附属同济医院 | miRNA biomarker for papillary thyroid carcinoma lateral cervical lymph node metastasis diagnosis and detection kit |
CN116769922B (en) * | 2023-08-24 | 2023-11-24 | 四川大学华西医院 | Application of reagent for detecting circulating sEV RNA, kit and diagnostic system |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011154008A1 (en) * | 2010-06-11 | 2011-12-15 | Rigshospitalet | Microrna classification of thyroid follicular neoplasia |
JP2014511677A (en) * | 2011-03-22 | 2014-05-19 | コーネル・ユニバーシティー | Distinguishing benign and malignant thyroid lesions that are difficult to distinguish |
EP2771487A1 (en) * | 2011-10-27 | 2014-09-03 | Asuragen, INC. | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors |
-
2015
- 2015-05-13 JP JP2016567582A patent/JP6216470B2/en not_active Expired - Fee Related
- 2015-05-13 WO PCT/US2015/030564 patent/WO2015175660A1/en active Application Filing
- 2015-05-13 CN CN201580024961.9A patent/CN106460053A/en active Pending
- 2015-05-13 CA CA2945531A patent/CA2945531C/en not_active Expired - Fee Related
- 2015-05-13 EP EP15792258.4A patent/EP3143162A4/en active Pending
- 2015-05-13 BR BR112016026575A patent/BR112016026575A2/en not_active Application Discontinuation
-
2016
- 2016-10-31 IL IL248639A patent/IL248639A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2017521051A (en) | 2017-08-03 |
IL248639A0 (en) | 2017-01-31 |
WO2015175660A1 (en) | 2015-11-19 |
CA2945531A1 (en) | 2015-11-19 |
EP3143162A4 (en) | 2017-04-26 |
CA2945531C (en) | 2018-01-30 |
EP3143162A1 (en) | 2017-03-22 |
CN106460053A (en) | 2017-02-22 |
JP6216470B2 (en) | 2017-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016026575A2 (en) | Mirna Expression Signature in Thyroid Tumor Classification | |
NZ741324A (en) | Anti-cd47 antibodies and methods of use | |
BR112018005164A2 (en) | antibodies, nucleic acid, host cell, method for producing an antibody, pharmaceutical formulation, use of the antibody and method of treating an individual who has cancer | |
BR112016005816A2 (en) | COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT TUMORS | |
BR112017012621A2 (en) | cyclic peptides with enhanced nerve binding selectivity, nanoparticles bound with said cyclic peptides, and their use for real time in vivo nerve tissue imaging | |
BR112016001611A2 (en) | MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFIC ACTIVABABLE ANTIBODIES AND METHODS OF THEIR USE | |
MX2016002051A (en) | Methods and kits for the molecular subtyping of tumors. | |
TR201812261T4 (en) | CANCER TREATMENT WITH PI3 KINASE ISOFORM MODULATORS | |
BR112016027222A2 (en) | isolated antibodies, isolated nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, methods of treating an individual with cancer, inhibiting cell proliferation, detecting human gpc3 and detecting a cancer | |
BR112017021312A2 (en) | Lung cancer treatment with glutaminase inhibitors | |
BR112019001398A2 (en) | Methods for Prostate Cancer Treatment | |
BR112017000714A2 (en) | functionalized and substituted indols as anti-cancer agents | |
BR112016023607A2 (en) | medical use of artemisinin compounds and gephyrin agonists | |
BR112015032758A2 (en) | docetaxel polymeric nanoparticles for cancer treatment | |
UY34812A (en) | METHOD FOR TREATMENT OF LUNG CANCER OF NON-SMALL CELLS | |
BR112016030172A2 (en) | specific aptamers for tlr-4 and their uses | |
BR112016011734A2 (en) | INDOLES SUBSTITUTED AND FUNCTIONALIZED AS ANTI-CANCER AGENTS | |
TR201909951T4 (en) | A method for predicting the outcome of aflibercept treatment of a patient suspected of having cancer. | |
EP4249608A3 (en) | Early lung cancer detection by dna methylation phenotyping of sputum-derived cells | |
BR112015010220A2 (en) | methods of using biomarkers for cancer treatment | |
EA201591742A1 (en) | METHOD FOR IMPROVING DIAGNOSTIC DISEASES USING MEASURED ANALYTES | |
BR112019006504A2 (en) | Avelumab Dosage Regimen For Cancer Treatment | |
BR112015027249A2 (en) | cancer diagnosis method | |
BR112018007394A2 (en) | process for producing an aqueous precipitate of calcium carbonate suspension, aqueous suspension of precipitate calcium carbonate, product, precipitate calcium carbonate, and use of an aqueous precipitate of calcium carbonate | |
BR112018003779A2 (en) | sialyl di-lewis a as expressed in glycoproteins but not glycolipids as a functional cancer target and antibodies to it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B65X | Notification of requirement for priority examination of patent application | ||
B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |